Molnupiravir

Q: **What is Molnupiravir?**

Molnupiravir is a medicine for treatment of mild-to-moderate COVID-19 disease. The U.S. Food and Drug Administration (FDA) authorized it for use in December 2021. Molnupiravir is used to treat infection. It cannot be used to prevent it.

Q: **Who is Molnupiravir for?**

Molnupiravir is for adults at high risk for severe COVID-19 disease who have tested positive for COVID-19. This includes people over 65 years old or who have conditions like cancer, heart disease, chronic lung conditions, or diabetes.

Molnupiravir is not recommended for children or people who are pregnant or breastfeeding.

Q: **How is it administered?**

Molnupiravir is taken by mouth. The usual dose is four tablets every 12 hours for five days. It is important to complete the full 5-day treatment course and continue isolation per public health recommendations. It should not be taken for more than five days.

Q: **Is Molnupiravir available now?**

Yes, but the supply at first will be very limited. Initially, it will be used for those at highest risk. As supply increases, it will become more broadly available.

For more information about Molnupiravir, read the patient information guide.

Document accessibility: For individuals with disabilities or individuals who speak a language other than English, OHA can provide information in alternate formats such as translations, large print, or braille. Contact the Health Information Center at 1-971-673-2411, 711 TTY or COVID19.LanguageAccess@dhsoha.state.or.us.